Sarasota Memorial Health Care System’s Kolschowsky Research and Education Institute is enrolling patients in a new clinical trial aimed at people with a genetic risk for heart disease. The study is evaluating whether the investigational drug dalcetrapib can reduce heart attacks and deaths in patients with a recent sudden cardiac event who test positive for the AA genotype, a variant in the ADCY9 gene linked to higher risk.
The phase 3 trial, sponsored by DalCor Pharmaceuticals, will enroll up to 2,000 participants across more than 200 research sites in North America. Eligible patients must be age 45 or older and recently hospitalized for a sudden cardiac event, or discharged within the past three months, and test positive for the specified genotype. Enrollment may occur during hospitalization or within 12 weeks following the event.
The study is randomized and placebo-controlled, with participants either receiving dalcetrapib or a placebo. Patients will be monitored at scheduled intervals throughout the trial to measure outcomes. Sarasota Memorial cardiologist Jeffrey Rossi, MD, is serving as the principal investigator for the local site.
For eligibility screening and enrollment information, call the Sarasota Memorial research team at 941-917-2225 or email researchinstitute@smh.com. Details on the national trial are available at clinicaltrials.gov. Pictured is principal investigator Jeffrey Rossi, MD.
